Salix Pharmaceuticals Ltd (SLXP) Misses Q2 EPS by 10c

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $1.59, $0.10 worse than the analyst estimate of $1.69. Revenue for the quarter came in at $382 million versus the consensus estimate of $397.06 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.

You May Also Be Interested In

• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c
• Grocery Outlet Holding Corp. (GO) Tops Q2 EPS by 8c, Offers Guidance